Inari Medical, Inc. (NASDAQ:NARI) Receives Consensus Rating of “Hold” from Analysts

Inari Medical, Inc. (NASDAQ:NARI) has earned a consensus rating of “Hold” from the fourteen analysts that are covering the stock, Marketbeat.com reports. Twelve research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $68.00.

NARI has been the subject of several recent research reports. Baird R W lowered shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. Piper Sandler increased their price objective on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 7th. Truist Financial increased their price objective on shares of Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Robert W. Baird reissued a “neutral” rating and issued a $80.00 price objective (down previously from $81.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research report on Tuesday, October 29th.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, Director William Hoffman sold 60,000 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the transaction, the director now directly owns 441,233 shares in the company, valued at $24,559,028.78. This represents a 11.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction on Friday, December 20th. The shares were sold at an average price of $55.29, for a total transaction of $165,870.00. Following the transaction, the chief executive officer now owns 439,310 shares in the company, valued at $24,289,449.90. This trade represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 263,000 shares of company stock worth $15,599,470 in the last ninety days. 10.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. boosted its stake in Inari Medical by 5.3% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,550 shares of the company’s stock valued at $130,000 after acquiring an additional 128 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Inari Medical by 0.9% in the 4th quarter. Arizona State Retirement System now owns 15,196 shares of the company’s stock worth $776,000 after buying an additional 129 shares during the last quarter. Quadrant Capital Group LLC lifted its position in shares of Inari Medical by 12.3% in the 4th quarter. Quadrant Capital Group LLC now owns 1,301 shares of the company’s stock worth $66,000 after buying an additional 143 shares during the last quarter. Ieq Capital LLC lifted its position in shares of Inari Medical by 0.3% in the 4th quarter. Ieq Capital LLC now owns 50,198 shares of the company’s stock worth $2,563,000 after buying an additional 145 shares during the last quarter. Finally, HighTower Advisors LLC lifted its position in shares of Inari Medical by 0.4% in the 4th quarter. HighTower Advisors LLC now owns 62,202 shares of the company’s stock worth $3,175,000 after buying an additional 234 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.

Inari Medical Price Performance

Inari Medical stock opened at $79.97 on Wednesday. Inari Medical has a 52-week low of $36.73 and a 52-week high of $79.99. The firm has a fifty day moving average of $72.43 and a 200-day moving average of $55.98. The firm has a market capitalization of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.